Inclusive of all taxes
Cefepime Hydrochloride & Tazobactam Sodium for Injection 281.25 mg is a potent combination antibiotic designed for intravenous or intramuscular administration, primarily used to combat infections caused by multi-drug resistant bacteria. This formulation combines Cefepime, a fourth-generation cephalosporin known for its broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, with Tazobactam Sodium, a beta-lactamase inhibitor that protects Cefepime from enzymatic degradation, thereby enhancing its efficacy against beta-lactamase producing pathogens. The product is supplied as a sterile, dry powder intended for reconstitution prior to injection. Its strength of 281.25 mg includes 250 mg of Cefepime and 31.25 mg of Tazobactam, offering optimal therapeutic dosage. This combination is highly effective in treating complicated urinary tract infections, pneumonia, skin and soft tissue infections, and intra-abdominal infections, particularly in hospital and clinical settings dealing with resistant bacterial strains. The drug exhibits excellent tissue penetration and is preferred by healthcare professionals for its reliable pharmacokinetic and pharmacodynamic profile in severe and hospital-acquired infections.
Key Features
| Features | Description |
|---|---|
| Form | Sterile dry powder for injection |
| Dosage Strength | 281.25 mg (250 mg Cefepime + 31.25 mg Tazobactam Sodium) |
| Generation | Fourth-generation cephalosporin combined with beta-lactamase inhibitor |
| Antibacterial Spectrum | Broad-spectrum activity against Gram-positive and Gram-negative bacteria, including resistant strains |
| Usage | Intravenous or intramuscular administration after reconstitution |
| Indications | Effective against complicated urinary tract infections, pneumonia, skin and soft tissue infections, intra-abdominal infections |
| Clinical Advantage | Enhanced efficacy against beta-lactamase producing bacteria due to Tazobactam |
| Sterility | Supplied as sterile powder ensuring high safety in clinical use |
| Attributes | Description |
|---|---|
| Active Ingredients | Cefepime Hydrochloride 250 mg + Tazobactam Sodium 31.25 mg |
| Formulation Type | Dry powder for injection |
| Route of Administration | Intravenous (IV) or Intramuscular (IM) |
| Reconstitution | Requires reconstitution with sterile water or recommended diluent prior to administration |
| Packaging | Vial containing 281.25 mg dry powder |
| Storage Conditions | Store below 25°C, protect from moisture and light |
| Shelf Life | Typically 24 months from manufacture date |
| Manufacturer Compliance | Manufactured under GMP with stringent quality controls |
| Pharmacological Class | Fourth-generation cephalosporin and beta-lactamase inhibitor combination |
| Common Indications | Nosocomial infections, severe bacterial infections, and resistant bacterial infections |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The combination enhances the antibiotic spectrum by protecting Cefepime from beta-lactamase enzyme degradation through Tazobactam's inhibitory action, making the drug effective against beta-lactamase producing resistant bacteria.
It is indicated for complicated urinary tract infections, pneumonia, skin and soft tissue infections, and intra-abdominal infections, especially those caused by resistant bacterial strains.
The sterile dry powder must be reconstituted with sterile water or a recommended diluent as per clinical guidelines before intravenous or intramuscular injection.
Yes, due to its broad-spectrum activity and enhanced resistance profile, it is highly effective against hospital-acquired infections caused by resistant organisms.
The product should be stored below 25°C in a dry place, protected from moisture and light to maintain its potency and sterility.
Country Of Origin: India
Cefepime Hydrochloride & Tazobactam Sodium for Injection 281.25 mg is a combination antibiotic that includes a fourth-generation cephalosporin with a beta-lactamase inhibitor, extending the efficacy of the drug against resistant bacteria. Here's an overview:
Cefepime Hydrochloride & Tazobactam Sodium for Injection 281.25 mg is a combination antibiotic that includes a fourth-generation cephalosporin with a beta-lactamase inhibitor, extending the efficacy of the drug against resistant bacteria. Here's an overview:
Key Features:
Form: Dry powder for injection.
Strength: 281.25 mg (combined dosage of Cefepime Hydrochloride and Tazobactam Sodium).
Cefepime: Typically 250 mg
Tazobactam: Typically 31.25 mg
Inclusive of all taxes
You Save: 0
